About Vaxart, Inc.
https://vaxart.comVaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform.
CEO
Steven Lo
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2018-02-14 | Reverse | 1:11 |
| 2012-11-09 | Reverse | 1:6 |
ETFs Holding This Stock
Summary
Showing Top 2 of 3
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
MARSHALL WACE, LLP
Shares:1.95M
Value:$1.07M
BLACKROCK INC.
Shares:1.77M
Value:$975.89K
RAYMOND JAMES FINANCIAL SERVICES ADVISORS, INC.
Shares:188.38K
Value:$103.61K
Summary
Showing Top 3 of 36
About Vaxart, Inc.
https://vaxart.comVaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $72.41M ▲ | $80.22M ▲ | $-8.14M ▲ | -11.24% ▲ | $-0.04 ▲ | $-5.44M ▲ |
| Q2-2025 | $39.73M ▲ | $54.33M ▲ | $-14.99M ▲ | -37.72% ▲ | $-0.07 ▼ | $-12.1M ▲ |
| Q1-2025 | $20.88M ▲ | $35.81M ▲ | $-15.59M ▼ | -74.68% ▲ | $-0.07 ▼ | $-12.25M ▼ |
| Q4-2024 | $15.19M ▲ | $26.68M ▲ | $-11.98M ▲ | -78.93% ▲ | $-0.05 ▼ | $-8.65M ▲ |
| Q3-2024 | $4.93M | $19.41M | $-14.08M | -285.42% | $-0.03 | $-11.21M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $28.79M ▲ | $208.99M ▲ | $182.23M ▲ | $26.76M ▼ |
| Q2-2025 | $26.27M ▼ | $164.09M ▲ | $131.21M ▲ | $32.88M ▼ |
| Q1-2025 | $41.94M ▼ | $158.56M ▼ | $112.94M ▲ | $45.62M ▼ |
| Q4-2024 | $51.72M ▼ | $166.39M ▼ | $107.46M ▲ | $58.92M ▼ |
| Q3-2024 | $58.71M | $166.67M | $98.23M | $68.44M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-8.14M ▲ | $2.6M ▲ | $-5.82M ▼ | $-4K ▼ | $-3.23M ▲ | $2.48M ▲ |
| Q2-2025 | $-14.99M ▲ | $-15.95M ▼ | $7.23M ▼ | $125K ▲ | $-8.59M ▼ | $-15.84M ▼ |
| Q1-2025 | $-15.59M ▼ | $-9.6M ▼ | $13.23M ▲ | $-164K ▼ | $3.47M ▲ | $-9.73M ▼ |
| Q4-2024 | $-11.98M ▲ | $-7.34M ▼ | $10.4M ▲ | $136K ▲ | $3.19M ▲ | $-7.39M ▼ |
| Q3-2024 | $-14.08M | $-4.2M | $-17.04M | $-10K | $-21.25M | $-4.21M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Government Contract | $0 ▲ | $70.00M ▲ | $70.00M ▲ | $70.00M ▲ |
 Non Cash Royalty Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Steven Lo
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2018-02-14 | Reverse | 1:11 |
| 2012-11-09 | Reverse | 1:6 |
ETFs Holding This Stock
Summary
Showing Top 2 of 3
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
MARSHALL WACE, LLP
Shares:1.95M
Value:$1.07M
BLACKROCK INC.
Shares:1.77M
Value:$975.89K
RAYMOND JAMES FINANCIAL SERVICES ADVISORS, INC.
Shares:188.38K
Value:$103.61K
Summary
Showing Top 3 of 36